Practitioner's Docket No. NEB-210

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

Kong, Huimin; Vincent, Myriam and Xu, Yan

Application No.: 10/665,633

Group No.: 1635

Filed: September 19, 2003

Examiner: Not yet assigned

For: Helicase Dependent Amplification of Nucleic Acids

Mail Stop Amendment **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

> TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR **BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))**

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b).

CERTIFICATION UNDER 37 C.F.R. " 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

37 C.F.R. § 1.10*

X with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee" Mailing Label No.

(mandatory)

TRANSMISSION

facsimile transmitted to the Patent and Trademark Office, (703)

Date: September 15, 2004

Leslie Goldberg

(type or print name of person certifying)

^{*} Only the date of filing ('1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under '1.8 continues to be taken into account in determining timeliness. See '1.703(f). Consider "Express Mail Post Office to Addressee" ('1.10) or facsimile transmission ('1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Date: September 15, 2004

Reg. No.: 37,008

Tel. No.: 978-927-5054 Customer No.: 28986 Signature of Practitioner Harriet M. Strimpel, D. Phil New England Biolabs, Inc.

32 Tozer Road

Beverly, MA 01915

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re application of:

Huimin Kong, Myriam Vincent and Yan Xu

plication No.: 10/665,633

Group No.: 1635

ed: September 19, 2003

Examiner: Not yet assigned

or: Helicase Dependent Amplification of Nucleic Acids

Mail Stop Amendment: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

- 1. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)
- 2. Copies of Listed Information Items Accompanying This Statement
- 3. Identification of Person(s) Making This Information Disclosure Statement

CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. § 1.8(a)

37 C.F.R. § 1.10*

X with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"

(mandatory)

TRANSMISSION

facsimile transmitted to the Patent and Trademark Office, (703) _

Signature

Mailing Label No.

Leslie Goldberg

Date: September 15,2004

(type or print name of person certifying)

^{*} Only the date of filing ('1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under '1.8 continues to be taken into account in determining timeliness. See '1.703(f). Consider "Express Mail Post Office to Addressee" ('1.10) or facsimile transmission ('1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Section 1. Forms PTO/SB/08A and 08B (formerly Form PTO-1449)

(Insert form(s) PTO/SB/08A [Form 6-2] and/or form(s) PTO/SB/08B [Form 6-2.1].)

Section 2. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.

AL-AM, BB-BD and DR-DS.

Section 3. Identification of Person Making This Information Disclosure Statement

The person making this certification is:

a. the practitioner who signs below on the basis of the information in the practitioner's file.

Date: September 15, 2004

Reg. No.: 37,008

Tel. No.: 978-927-5054 Customer No.: 28986 Signature of Practitioner Harriet M. Strimpel, D. Phil New England Biolabs, Inc.

32 Tozer Road Beverly, MA 01915

SECTION 2. FORMS PTO/SB/08A and 08B (formerly Form PTO-1449)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Kong et al.

Atty. Docket:

NEB-210-US

Serial No:

10/665,633

Art Group Unit:

1635

Date Filed:

09/19/2003

Examiner Name:

Not yet assigned

Invention:

Helicase-Dependent Amplification of Nucleic Acids

SUPPLEMENTAL LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS					
·Examiner	Reference	Document	Issue / Pub	Inventor	Class/Subclass
Initials	Number	Number	Date		
	AL	6,306, 588 B1	10/23/2001	Solus et al.	C12Q
	AM	6,214,587 B1	04/10/2001	Dattagupta et al.	C12P

	FOREIGN PATENT DOCUMENTS					
Examiner	Reference	Country	Document	Publication	Patenteee	Class/Subclass
Initials	Number	Code	Number	Date	or	
					Applicant	
	BB	wo	00/41524	2000-07-20	President and Fellows of Harvard College	Not classified
	BC	WO	99/37820	1999-07-29	Saigene Corporation	C12Q
	BD	WO	01/025473	2001-04-12	Source Precision Medicine	C12Q

OTHER DOCUMENTS				
Examiner	Examiner Reference Author Title of Article, Title of Journal, Volume			
Initials	Number		Number, Page Numbers, Date	
	DR	Gorbalenya et al.	Curr. Opin. Struct. Biol. 3:419-429 (1993).	
	DS	Komberg et al.	DNA Replication, W.H. Freeman Company, NYC (2nd ed) (1992) pp.355-378.	



Examiner Signature:
Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant